Biopeople working group on personalised medicine
Biopeople’s focus on biomarkers and personalised medicine is based on the increasingly importance of a molecular understanding of diseases and the role of biomarkers as diagnostics. The project ’Biomarkers – an emerging growth area’, a collaboration between Biopeople and the innovation networks InfinIT, Brandbase and the GTS institution Bioneer A/S, which closed in 2018, published a white paper about infra structures in the Danish biomarker community.
Following that project, Biopeople established a working group in personalised medicine with participation of the Danish Medicines Agency, Rigshospitalet, Danish universities and several Danish companies.
Working Group objective
The project ’Biomarkers – an emerging growth area’, a collaboration between Biopeople and the innovation networks InfinIT, Brandbase and the GTS institution Bioneer A/S, which closed in 2018, published a white paper about infra structures in the Danish biomarker community.
Following that project, Biopeople established a working group in personalised medicine with participation of the Danish Medicines Agency, Rigshospitalet, Danish universities and several Danish companies. The objective of the working group is to
- Strengthen the national network of players in the biomarkers and personalised medicines field
- Communicate and disseminate information about legislation and legal requirements regarding personalised medicine
- Catalyse and facilitate collaboration and knowledge sharing between public and private partners nationally and internationally
- Support patient advocacy and involvement in the development of personalised medicine
The working group hosted in September 2019 a dialogue meeting regarding the new EU regulation (2017/746/EU) for in vitro diagnostic. Another event in the spring of 2020 will focus on the development of biomarkers and diagnostics. At the meeting companies, hospitals, patient organisations and universities will share knowledge, establish new relationships and develop the field.
Background: 20 years with personalised medicine
Twenty years ago a Wall Street Journal article introduced the term ’personalised medicine. It happened at the starting-up of a collaboration between pharmaceutical companies and research groups supported by the Wellcome Trust Foundation.
The collaboration aimed to develop a database of known types of human gene sequences hoping that this would lead to more effective medicines and individualised treatments. The valuable knowledge based on individual people’s DNA may result in personalised new treatments for diseases.
The right medicine……
Through decades people in the health care sector has had personalised treatment on the agenda especially with relation to medical treatment. As early as in the 1960’ies and 1970’ies the term rational pharmacotherapy developed. The mantra was: ”The right medicine for the right patient at the right time.”
“Today, when discussing personalised medicine, the same terms are often used. The major difference between that time and now is the knowledge we have gained through huge technological progress within molecular medicine,” says Jan Trøst Jørgensen, Director, Dx-Rx Institute and member of the working group. He explains: “New diagnostic methods have produced a better molecular understanding of the pathophysiology of the various diseases and the effect of the medicines. This is pivotal for individualised treatment. Molecular medicine have given new knowledge of the individual diseases. Concurrently it has been obvious that diseases often are of a heterogeneous nature. This is important to understand when starting the right treatment. A brief summary of what personalised medicine is could be the use of molecular diagnostics to improve treatment of the individual patient and to prevent diseases.”
Biomarkers play an increasingly important role
The increasing molecular understanding of diseases means that biomarkers play an increasingly important role in the development of new medicines and treatment. Through the last 20 years, a companion biomarker diagnostic has accompanied an increasing number of new medicines, a so-called pharmacodiagnostic test. The aim is to use it to identify the patients who will benefit the most from a certain medical treatment.
Huge – but unexploited potential
In spite of the technological progress and increased knowledge about the pathophysiology of the individual diseases and the mechanism of action of medicines, there are still challenges ahead. Today most patients with serious chronic diseases receives treatment with medicines based on a ‘trial and error’ principle. It does not happen based on biomarker data. Jan Trøst Jørgensen stresses the fact that the treatment potential is still unexploited. “It is a potential, which ultimately may lead to more effective treatment, less adverse reactions, less sick days or less days at the hospital – which means a significant reduction of health care costs. At the same time, the business potential is huge. One of Denmark’s most competitive sectors today is a value chain of researchers and companies with a focus in personalised medicine.”
Members of the working group in personalised medicine
Martin Højgaard – Region Hovedstaden
Hans Christian Pedersen – Unilabs A/S
Magdalena Janina Laska – AimVion A/S
Frederik Grell – Lægemiddelstyrelsen
Lars Gersdorff – Agilent Technologies Denmark ApS
Jan Trøst Jørgensen – Dx-Rx Institute ApS
Valerie Daussin Laurent – Region Nordjylland